MitoQ treatment for leg pain caused by poor blood flow
MitoQ treatment of claudication: myofiber and micro-vessel pathology
This study is looking at whether taking MitoQ, an antioxidant, can help people with leg pain from poor blood flow feel better, walk more easily, and enjoy life more over six months.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11099749 on NIH RePORTER |
What this research studies
This research investigates the effects of MitoQ, an antioxidant, on patients suffering from claudication, a condition characterized by leg pain due to poor blood flow. The study aims to determine whether long-term treatment with MitoQ can improve walking performance, daily physical activity, and overall quality of life for these patients. By focusing on the underlying mitochondrial dysfunction that contributes to muscle pain, the research seeks to provide a new therapeutic option for individuals with Peripheral Artery Disease (PAD). Patients will be monitored for changes in calf muscle health and functional performance over a six-month treatment period.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with claudication due to Peripheral Artery Disease who experience leg pain during physical activity.
Not a fit: Patients who do not have claudication or those with other underlying conditions that prevent participation in the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with claudication, significantly improving their mobility and quality of life.
How similar studies have performed: Previous studies have shown that MitoQ is safe and effective in improving outcomes for patients with mitochondrial dysfunction, suggesting potential success for this novel application.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Pipinos, Iraklis Ilias — University of Nebraska Medical Center
- Study coordinator: Pipinos, Iraklis Ilias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.